CRISPR-engineered T cells in patients with refractory cancer

Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Abramson Cancer Center.

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Penn study shows potential of interferon pathway as biomarker, therapeutic target

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

New Protocol for Clinical Proteomics

A team from Penn and the commercial lab ProtiFi presented an optimized workflow using formalin-fixed, paraffin-embedded (FPPE) tissue archives.

Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

Featured in the NIH Director's Blog

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Cancer cells are more than a lump of cells growing out of control; they participate in active combat with the immune system for their own survival.